All In Biotech

Drug Trial Radar · NCT06659445

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

A Phase 2 Multicenter, Randomized, Double-masked, Sham-controlled, Reference-arm Study to Evaluate Efficacy and Safety of ONL1204 in Patients With Geographic Atrophy (GA) Associated With Age-related Macular Degeneration (AMD)

Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 324 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

324

Planned (sponsor's estimate)

Start

Oct 28, 2025

Primary completion

Nov 2028

Study completion Nov 2028

Sponsor

Lead sponsor
ONL TherapeuticsIndustry
Sponsor type
Industry
First posted
Oct 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to collect efficacy and safety information of intravitreal injection for 3 experimental arms, including 2 dose levels of ONL1204 and 2 treatment frequencies in patients with GA associated with AMD. GA associated with AMD is one of the world's leading causes of visual disability and legal blindness globally. Associated with aging, cigarette smoking, obesity, diets low in certain nutrients, a lifestyle related to cardiac risk, and a growing list of genetic factors, AMD is becoming an increasingly prevalent public health concern, especially as the global population ages. ONL1204 is a first-in-class inhibitor of fragment apoptosis stimulator receptor-mediated cell death that has demonstrated protection of multiple retinal cell types in numerous preclinical models of retinal disease, including models of dry AMD.

Conditions

  • Geographic Atrophy (GA)
  • Age - Related Macular Degeneration (AMD)

Interventions

  • ONL1204 Opthalmic solutionDrug

    Liquid formulation ONL1204 Ophthalmic Solution administered by intravitreal (IVT) injection

  • Avacincaptad Pegol intravitreal solutionDrug

    Liquid formulation Avacincaptad Pegol administered by intravitreal (IVT) injection

  • ShamOther

    Sham injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary EndpointTime frame: From enrollment to the end of treatment at 48 weeks.

Locations

120 sites in 12 countries. Site status is shown where the registry gives one.

  • Associated Retina Consultants

    Gilbert, Arizona · Recruiting

  • Associated Retina Consultants

    Phoenix, Arizona · Recruiting

  • California Retina Consultants

    Bakersfield, California · Recruiting

  • Retina-Vitreous Associates Medical Group

    Beverly Hills, California · Recruiting

  • Macula and Retina Institute

    Glendale, California · Recruiting

  • Salehi Retina Institute, dba Retina Associates of Southern California

    Huntington Beach, California · Recruiting

  • Desert Retina Consultants

    Palm Desert, California · Recruiting

  • Retinal Consultants Medical Group

    Sacramento, California · Recruiting

  • Bay Area Retina Associates

    Walnut Creek, California · Recruiting

  • Retina Consultants of Southern Colorado

    Colorado Springs, Colorado · Recruiting

  • Retina Group of New England

    Waterford, Connecticut · Recruiting

  • Florida Retina Institute

    Orlando, Florida · Recruiting

  • Retina Specialty Institute

    Pensacola, Florida · Recruiting

  • Retina Group of Florida

    Sarasota, Florida · Recruiting

  • Retina Associates of Florida, LLC

    Tampa, Florida · Recruiting

  • Northwestern Medical Group

    Chicago, Illinois · Recruiting

  • The University of Chicago Medicine Duchossois Center for Advanced Medicine

    Chicago, Illinois · Recruiting

  • Retina Associates, Ltd.

    Elmhurst, Illinois · Recruiting

  • Illinois Retina Associates, S.C.

    Oak Park, Illinois · Recruiting

  • Retina Partners Midwest, P.C.

    Carmel, Indiana · Recruiting

  • The Retina Group of Washington

    Chevy Chase, Maryland · Recruiting

  • Cumberland Valley Retina Consultants

    Hagerstown, Maryland · Recruiting

  • Retina Specialists

    Towson, Maryland · Recruiting

  • Retina Research Institute at New England Retina Consultants

    Springfield, Massachusetts · Recruiting

  • University of Michigan Kellogg Eye Center

    Ann Arbor, Michigan · Recruiting

  • Associated Retinal Consultants, P.C.

    Royal Oak, Michigan · Recruiting

  • Associated Retinal Consultants, P.C.

    Traverse City, Michigan · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • The Retina Institute

    St Louis, Missouri · Recruiting

  • Sierra Eye Associates

    Reno, Nevada · Recruiting

  • Retina Vitreous Surgeons of CNY, PC

    Liverpool, New York · Recruiting

  • Ophthalmic Consultants of Long Island

    Oceanside, New York · Recruiting

  • Retina Associates of Western NY

    Rochester, New York · Recruiting

  • Long Island Vitreoretinal Consultants

    Westbury, New York · Recruiting

  • North Carolina Retina Associates

    Cary, North Carolina · Recruiting

  • Duke Eye Center

    Durham, North Carolina · Recruiting

  • North Carolina Retina Associates

    Greenville, North Carolina · Recruiting

  • North Carolina Retina Associates, S.C.

    Wake Forest, North Carolina · Recruiting

  • Cleveland Clinic Foundation-Cole Eye Institute

    Cleveland, Ohio · Recruiting

  • Erie Retina Research, LLC (Clinic)

    Erie, Pennsylvania · Recruiting

Showing 40 of 120 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.